Editorial
Volume 3 Issue 2 - 2016
HPV Infection and Cervical Cancer. Prevention Opportunities
Petya Kostova*
Gynecology Clinic, National Oncology Hospital, Bulgaria
Corresponding Author: Petya Kostova, Gynecology Clinic, National Oncology Hospital, Plovdivsko pole street 6, Sofia, Bulgaria.
Received: July 12, 2016; Published: July 13, 2016
Citation: Petya Kostova. “HPV Infection and Cervical Cancer. Prevention Opportunities”. EC Gynaecology 3.2 (2016): 262-265.
Abstract
Cervical cancer remains a medical and social problem for our country and requires the implementation of effective strategy for its prevention. The etiopathogenesis of precancer lesions and cervical cancer is associated with the human papillomavirus infection. The proof of the biological significance of papillomavirus infection led to the need to identify the role of individual HPV types, and thus to the rapid development of various specialized virological techniques. The introduction of HPV vaccines does not waive the need of regular screening examinations with Pap smear. The widespread use of cytologic screening, improving the sensitivity of the screening test and the application of HPV vaccines are an actual opportunity to reduce cervical cancer incidence.
Keywords: Human papillomavirus infection; Cervical cancer; Prevention opportunities
Introduction
Cervical cancer (CC) is the fourth most common malignant tumor in women worldwide, with about 530000 new cases per year, accounting for almost 12% of all neoplasia in female population. Approximately 270000 deaths of CC are reported globally, representing thus 7.5% of all women who have died of cancer. If the current trend of increasing incidence of the disease continues, more than 1 million new cases may be expected in 2050 [1].
The significance of the problem is further confirmed by the fact that CC is included in the political declaration of the 2011 UN General Assembly Summit for Prevention and Control of Noncommunicable Diseases. In 2013 the World Health Assembly included CC among the priorities of the 2013 - 2020 Action Plan for Prevention and Control of Noncommunicable Diseases.
In Bulgaria, in the recent years, 1,100 new cases were diagnosed, and the death cases are over 350. Nationwide, it is one of the five most common malignancies in women, accounting for 6.5% of all neoplasia [2]. Another unfavorable indicator is the low frequency of pre-invasive forms, which is maintained during the recent years. This defines CC as a medical and social problem for our country and requires the implementation of effective strategy for its prevention.
In the last 30 years, the etiopathogenesis of precancer and cervical cancer is associated mainly with the Human papillomavirus (HPV) infection. In 1983 zur Hausen found HPV in precancer lesions, and in 1985 he described an active transcription of the virus in cancer cells, for which he was awarded the Nobel Prize for medicine in 2008 [3] that marked the beginning of numerous studies that confirmed the place of HPV in the etiology of anogenital neoplasma. Some authors found evidence of papilloma infection in 99% of cervical carcinoma cases [4,5].
Human papillomaviruses are DNA viruses hosted by squamous and metaplastic cells. Genital HPV infection is transmitted mainly by sexual intercourse and is usually observed in the beginning of the sexual life of individuals [6]. It is believed that about 60% of the female population encounter the papilloma virus at least once in their lives, while for most of them the infection is transient [7].
So far about 200 different types of HPVs have been reported, out of which approimately 50 affect the genital tract [8,9]. Their classification is made on the basis of phenotypic characteristics and their nucleotide sequence. Individual HPV types are defined through genomic analysis and actually represent genotypes [10,11].
The biological effects of papilloma viruses are determined mainly by their oncogenic significance. Most often, they are divided into two main groups. The first one includes HPV types associated with benign mucocutaneous changes-types 6 and 11. The second one is associated primarily with the appearance of precancerous and cancerous lesions, out of which 20 are associated directly with CC [13]. Out of them, 16 and 18 are responsible for 70% of cases with CC, 50% for high-grade intraepithelial lesions, and 4 - 25% for low-grade pre-cancerous changes of the cervix [11].
Most cervical changes caused by HPV infection will not progress to invasive carcinoma, even if they remain untreated. The variance between the high incidence of HPV infection and the relatively low incidence of CC shows stepwise gradient - of an increasing burdern and decreasing frequency between these conditions. It is believed that in 3 - 10% of women elimination of the viral infection is not achieved, and it persists at a high risk to progress to CC [12].
The main task of primary prophylaxis is to prevent a disease and therefore it is applicable to these forms of malignant tumors, for which there are convincing evidence of their etiological factors [13].
Proving the viral etiology of a given disease is a prerequisite to focus the efforts on the development of specific antiviral vaccines for prevention and treatment [14].
Both authorized anti-HPV vaccines have been produced by using recombinant DNA technology. The antigen is L1 capsid HPV protein, while proteins self-assemble into noninfectious and non-oncogenic units called virus-like particles (VLP), which ensure required immune response through the proliferation of CD4 + and CD8 + T cells and Th1 and Th2 cytokines [13].
The target population of prophylactic vaccines are girls over 10 years of age, as the goal is to prevent the persistent infection, cytological and histological abnormalities associated with HPV 16/18 and ultimately - the development of CC.
The results of comprehensive clinical studies of authorized HPV vaccines convincingly demonstrate their high protective activity. They show efficacy of over 90% in terms of preventing precancerous changes and CC, causally related to vaccine oncogenic types. Data from clinical studies show that both vaccines feature a good immunogenicity and safety profile.
The main target group for vaccination are girls prior to sexual onset - the objective is the formed postvaccination antibodies to protect them against an oncogenic HPV infection by preventing the entering of the virus into the cells of the cervical epithelium [14].
The new WHO guide on cervical screening, accepted by the World Cancer Congress, Melbourne (2014), recommends vaccination with HPV vaccine to girls from the age of 9 to 13 years, with at least two doses. The vaccine prevents the infection with viruses responsible for most cases of CC, while studies have shown that the administration of two doses was as effective as three. According to WHO, this will facilitate the administration of the vaccine and will reduce the price [15].
The introduction of HPV vaccines does not waive the need of regular screening examinations with Pap smear due to the delayed effect of immunization. Furthermore, 30% of the cases of cervical cancer are caused by HPV types, which are not included in the vaccine.
The secondary prevention combines methods to detect malignant tumors at an early stage, or at a stage prior to the development of cancer. The most effective form of secondary prevention appear to be screening tests. They are actively targeted to different population groups, in the absence of a need for medical examination or signs of disease [13].
There are various types of screening. In CC, the organized, population based cytological screening is deemed effective. It may reduce cancer mortality, and in the cases when precancerous conditions are detected and treated – it may lower incidence. If a range of at least 70% of the underlying population is achieved, it is possible to reduce advanced cancers by more than 30% and the mortality rate - by more than 15% [13].
The classic cervical screening is carried out by applying the cytologic method of G.Papanicolaou-L.Koss, which has a sensitivity of 81 - 85% and specificity of 95 - 98% [13]. It is well known that the cytology test has a low diagnostic value for detection of HPV infection. Hence the interest in the detection of HPV to increase the effectiveness of CC screening programs [11].
The prevalence of subclinical and transient HPV infections makes the detection of the virus insufficiently effective means of identifying women at risk to develop CC. DNA-based methods to determine HPV show only the presence of the virus, but not its oncogenic activity, as it is impossible to distinguish between active and latent or transient infection. More recent techniques based on determining the expression of mRNA of the viral E6/ E7 oncogenes improve the diagnostic capabilities by showing the initiation of the process of malignant transformation of cells at a very early stage.
In recent years, the concept of cervical screening attempts to implement some new modern methods that can be summarized in the following directions:
✔ Cytology test: automated cytoanalysis and monolayer smears technique.
✔ Imaging diagnostic methods: visual inspection, digital cervicography, opto-electronic analysis.
✔ Molecular biomarkers: HPV-testing and other new genetic markers.
Conclusion
We may summarize that the widespread use of cytologic screening, improving the sensitivity of the screening test and the application of HPV vaccines are an actual opportunity to reduce CC incidence.
Bibliography
  1. Schiffman M and D Solomon. “Cervical cancer screening with human papillomavirus and cytologic contesting”. New England Journal of Medicine 369.24 (2013): 2324-2331.
  2. Dimitrova N., et al. “Cancer Incidence in Bulgaria 2010, Bulgarian National Cancer Registry, AVIS-BG Ltd, Sofia, XXI (2012): 96.
  3. Weinstein LC., et al. “Screening and prevention: cervical cancer”. Primary Care: Clinics in Office Practice 36 (2009): 559-574.
  4. Hiller T and T Iftner. “The papilloma virus”.In: HPV handbook. Ed. By: W. Prendiville, Ph. Davies. Taylor & Francis. (2004): 11-26.
  5. Mougin C., et al. “Epidemiology of cervical papillomavirus infections”. Recent knowledge Presse Medicine 30 (2001): 1017-1023.
  6. Guerra B., et al. “Human papillomavirus in pregnancy”. The Cervix & lFGT 9 (1991) 81-85.
  7. Guidelines for the medical management of genital HPV and/or genital warts in Australia and New Zealand, 4th edition, Viral Sexually Transmitted Infection Education Foundation (2004): 25.
  8. Stern PL and MA Stanley. “Human papillomaviruses and cervical cancer”.In Biology and immunology. Oxford Univ. Press New York (1994): 1-226.
  9. Heley S. “Human papillomavirus: beware the infection you can’t see”. Australian family Physician 32.5 (2003): 311-315.
  10. IARC. “Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses”. IARC, Lyon 64 (1995) 379.
  11. Hiller T and T Iftner. “The papilloma virus”. In: HPV handbook. Ed. By: W. Prendiville, Ph. Davies. Taylor & Francis. (2004): 11-26.
  12. Monsonego JF., et al. “Cervical cancer control, priorities and new directions”. International Journal of Cancer 108.3 (2004): 329-333.
  13. Zlatkov V and P Kostova. “Prophylaxis, screening and vaccines in pre-cancer and cervical cancer”. Bulgarian publishing house, Sofia (1996): 149.
  14. National program for primary prophylaxis of cervical cancer in Bulgaria 2012-16.
  15. Comprehensive cervical cancer control. “A guide to essential practice”. 2nd edition. World Health Organization. WHO Library Cataloguing-in-Publication Data (2014): 364.
Copyright: © 2016 Petya Kostova. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events

November Issue Release

We Always feel pleasure to share an update with you all. Here, notifying you that we have successfully released November issue for the respective journals and can be viewed in the current issue pages.

Submission Deadline for January Issue

E-Cronicon delightfully welcome all the authors around the globe for an effective collaboration with an article submission for the January issue of respective journals. Submissions are accepted on/before December 17, 2019.

Certificate of Publication

E-Cronicon honours with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Special Issue Update for the Month of November

Editorial office of E-Cronicon (EC) is here with a great initiation to plan a special edition for the month of November. This special edition is intend to concentrate on new helpful, innovative solutions that are aimed at ensuring better quality in the management of treatment. We firmly believe that sharing of experience and visionary ideas will give beginning to solutions that will give hope for increased effectiveness in the prevention and treatment of various health issues which is considered to be an epidemic of the researchers and society. We would like to encourage you to participate in this unique edition so that we can work together to develop an optimistic concept for a better health perspective for patients. I hope to have the participation of every author who are in association with E-Cronicon to this special issue by making it a successful initiation. List of journals planning for November special edition: 1. EC Ophthalmology (ECOP) 2. EC Paediatrics (ECPE) 3. EC Pulmonology and Respiratory Medicine (ECPRM) 4. EC Gastroenterology and Digestive System (ECGDS) 5. EC Cardiology (ECCY). More information can be found in the special issue pages of these journals. Best paper will be picked by the Editorial office and will be provided with an "Appreciation Certificate". Take a smallest step by dropping your opinions to editor@ecronicon.uk for a biggest success.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

E-Cronicon certify the Editors for their first review done towards assigned article of the respective journals.

Latest Articles

Latest articles will be updated immediately in the articles in press page of the respective journals.

Immediate Assistance

Prime moto of this team is to clarify all the queries without any delay or hesitation in order to avoid the inconvenience. For an immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk